BioMed Research International / 2013 / Article / Tab 2

Review Article

Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectives

Table 2

Pharmacologic properties of direct-acting anti-HCV agents in clinical development, modified by Liang and Ghany [71].

PropertyNS3-4A protease inhibitors

Genotypic coverageNarrow (second generation drugs have broader coverage)
Probability of drug resistanceHigh
Side effectsSubstantial
Drug-drug interactionsSubstantial

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.